CAS (125-69-9) Weight Loss Drugs Dextromethorphan Hydrobromide Dextromethorphan

Basic info.

Product Name: Dextromethorphan Hydrobromide

Alias: Romilar, Tussade

CAS: 125-69-9

MF: C18H26BrNO

MW: 352.31

EINECS: 204-750-1

Storage: Ventilation low temperature drying

Product Categories: Medicine intermediate;Steroid and Hormone

Description:

Dextromethorphan (DXM or DM) is an antitussive (cough suppressant) drug. It is one of the active ingredients in many over-the-counter cold and cough medicines, including generic labels and store brands, Benylin DM, Mucinex DM, Robitussin, NyQuil, Dimetapp, Vicks, Coricidin, Delsym, TheraFlu, and others. Dextromethorphan has also found other uses in medicine, ranging from pain relief to psychological applications. It is sold in syrup, tablet, spray, and lozenge forms.In its pure form, dextromethorphan occurs as a white powder.

DXM is also used recreationally. When exceeding label-specified maximum dosages,dextromethorphan acts as a dissociative hallucinogen. Its mechanism of action is via multipleeffects, including actions as a nonselective serotonin reuptake inhibitor and a sigma-1 receptor agonist.DXM and its major metabolite, dextrorphan, also acts as an NMDA receptor antagonist at high doses, which produces effects similar to, yet distinct from, the dissociative states created by other dissociative anaesthetics such as ketamine and phencyclidine. As well, the metabolite 3-methoxymorphinan of dextrorphan (thus a second-level metabolite of DXM) produces local anesthetic effects in rats with potency above dextrorphan, but below that of DXM.

Applications:

Generic Dextromethorphan syrup.The primary use of dextromethorphan is as a cough suppressant, for the temporary relief of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants.

A 2004 study showed that dextromethorphan was no more effective for children than a placebo. Studies conducted by the American Academy of Pediatrics show that dextromethorphan is not superior to a placebo in providing nocturnal symptom relief for children with cough and sleep difficulty due to upper respiratory infections.

A combination of dextromethorphan and quinidine, a CYP2D6 inhibitor, has been shown to alleviate symptoms of easy laughing and crying (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis.Dextromethorphan is also being investigated as a possible treatment for neuropathic pain and pain associated with fibromyalgia.In 2010, the FDA approved the combination product dextromethorphan/quinidine (Nuedexta) for the treatment of pseudobulbar affect (PBA).

Dextromethorphan has been shown to be effective in treating opioid withdrawal. At doses of 2 mg/kg in rats all signs of opioid withdrawal were eliminated.